# Prelude Therapeutics (PRLD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PRLD
## Company Profile
- Ticker: PRLD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 5.73 USD
- Market cap: 278758574.5 USD
- Last updated: 2026-08-12
## Business Overview
### Precision Oncology Company
Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition.
### PRT12396
PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis.
### PRT13722
PRT13722 is an oral KAT6A degrader intended for hormone-receptor-positive breast cancer and other KAT6A-dependent tumors.
### Degrader Antibody Conjugates
Prelude is also applying its targeted protein degradation expertise to degrader antibody conjugates, including programs directed at mutant calreticulin in myeloproliferative neoplasms.
## Why The Stock Is Moving

Following the latest company update, “Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update”, PRLD closed up 10.1% at $5.32 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Initiation of a Phase 1 study of PRT13722 in hormone-receptor-positive breast cancer in the fourth quarter of 2026, pending IND clearance.

## Recent News
- 2026-08-11 11:00 EST — [Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-second-quarter-2026-financial-results-and-provides--a56ce7c8) — Source: Prelude Therapeutics
- 2026-05-12 11:01 EST — [Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Prelude Therapeutics
- 2026-04-20 10:30 EST — [Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering) — Source: Prelude Therapeutics
- 2026-04-20 10:00 EST — [Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026) — Source: Prelude Therapeutics
- 2026-04-15 11:30 EST — [Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer) — Source: Prelude Therapeutics